Axogen reported higher third-quarter revenue and earnings, with sales rising 26.2% from a year earlier. The peripheral-nerve repair company also raised its full-year revenue outlook, now projecting growth of at least 29%, or revenue of at least $290 million.
The company posted its quarterly results presentation and an updated corporate presentation alongside the announcement.
Key details
- Revenue reached $75.8 million for the quarter ended Sept. 30, up from $60.1 million a year earlier.
- Gross margin was 74.8%, compared with 76.6% in the third quarter of 2025, a decline of 1.8 percentage points.
- Net income increased to $2.3 million, or 4 cents per share, from $700,000, or 1 cent per share, a year earlier.
- Adjusted net income was $13.1 million, or 21 cents per share, versus $6.1 million, or 12 cents per share, in the prior-year quarter.
- Full-year revenue guidance was raised to at least $290 million, equivalent to growth of at least 29%. The announcement did not provide the previous guidance figure.
Plain-English implications
Axogen’s reported sales and earnings improved year over year, while gross margin eased. The higher revenue outlook signals the company now expects full-year sales growth of at least 29%; the announcement did not specify what prompted the increase.